阳光诺和(688621.SH)：ABA001注射液临床试验申请获得受理

Core Viewpoint - Sunshine Nuohua (688621.SH) has received the acceptance notice from the National Medical Products Administration for the clinical trial application of its research project ABA001 injection, which aims to treat hypertension [1] Group 1: Product Overview - ABA001 injection is a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) messenger RNA, utilizing an N-Acetylgalactosamine (GalNAc) delivery system to precisely deliver the drug to liver cells [2] - The drug works by silencing AGT mRNA through the siRNA interference mechanism, effectively blocking the synthesis of AGT protein and inhibiting the Renin-Angiotensin-Aldosterone System (RAAS) that raises blood pressure [2] - Non-clinical studies indicate that a dosage of 1 mg/kg can significantly lower blood pressure, demonstrating good tolerance in animals and high safety, with the potential for long-acting effects allowing administration every three months or six months [2]